Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels. Beovu ...

Is the Beovu Brolucizumab Market Poised for Significant Growth? The Beovu brolucizumab market has witnessed remarkable expansion in recent years and is expected to experience substantial growth in ...